Monocyte chemoattractant protein 1 (MCP-l) plays a crucial role in the migration and activation of leukocytes in both physiological and pathological contexts. In this paper, we report the ill vitro effect of MCP-l on myeloid haematopoiesis. MCP·l-treated murine nonadherent bone marrow cells (NABMCs) were assayed for ill vitro proliferation and colony forming ability. It is observed that MCP-l treatment ill vitro caused an enhancement in the proliferation and colony forming ability of the murine NABMCs as compared to the untreated cells. This response was concentration-dependent and most effective at a dose of lOOng/ml MCP-l. In the presence of MCSF (200U/ml), GCSF (200U/ml), GMCSF (200Ulml) or IL-3 (200U/ml), the MCP-l-induced colony forming ability of the NABMCs was significantly augmented, indicating a synergistic effect ofMCP-l with these CSFs. However, irrespective of the CSFs used, MCP-1 stimulated the lineage-restricted differentiation of the murine BMCs into predominantly the granulocytic lineage. NABMCs cultured in medium alone formed minimal colonies. The probable signal transduction mechanism responsible for the MCP-l-induced NABMC proliferation/differentiation was also investigated. The results of the colony forming assay indicate that the protein kinase inhibitors, genistein (l0llg/ml), chelenthryin chloride (lOIlM), wortmannin (200nM) and PD98059 (lOIlM) significantly blocked the ill vitro colony forming ability of the MCP-l-treated NABMCs, while the phosphatase inhibitors, okadaic acid (lOnM) and sodium orthovanadate (lOIlM) caused an increase in the BMC colony forming ability in response to MCP-l. These data suggests the involvement of the respective protein kinases and phosphatases in the above process. Correlating with this, the role of several signaling molecules likes Lyn, p42/44MAPK, PI3K and STAT5 has also been implicated in the signal cascade of murine NABMC proliferation/differentiation following MCP-l treatment.
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mobilization of bone marrow HPCs to peripheral blood [3, 5] .
One of the first haematopoietic regulatory activity for the chemokines was demonstrated for the CC-chemokine, MIP-I a. MIP-I a was shown to enhance the proliferation and colony formation of granulocytes/macrophages (CFU-GM) and macrophage (CFU-M) progenitor cells in vitro, a direct effect on mature subsets of myeloid progenitor cells that responded to stimulation by GMCSF or MCSF [6, 7] . However, further in vitro and in vivo studies have revealed a myelosuppressive effect of this chemokine on the proliferation of mature subsets of HPCs, stem/progenitor cells, an observation which has been extended to a number of other chemokines of CC and CXC groups [8] . Today, atleast 30 chemokines are known to exert suppressive, nonsuppressive or enhancing effect on myeloid haematopoiesis, confirming their regulatory role in HPC proliferation and mobilization [5] .
Monocyte chemoattractant protein-l (MCP-I) represents one of the most widely studied members of the chemokine family. Both in vitro and in vivo studies with transgenic animal models have indicated MCP-I to be a key mediator of monocyte/macrophage infiltration at the site of inflammation and malignancies [9, I0] . In addition to its potent chemotactic effect, MCP-I is known to exert multiple in vitro functions on various cell types. These include increase in cytosolic calcium, superoxide anion production, lysosomal enzyme release, production of IL-I, IL-6 and regulated expression of surface adhesion molecules in monocytes [11, 12] ; polarization of Tlymphocytes into T-helper2 cells [13] ; stimulation of histamine release from basophils [14] and increase in NK cell activity [15] . Recent data have shown MCP-I to playa crucial role in a number of diseased states such as atherosclerosis, rheumatoid arthritis, asthma and cancer [9] . Together, these studies have evoked much interest in this chemokine and have made it an important target for therapeutic manipulations in treating different pathophysiological states. However, in spite of these reports, little is known about the role of MCP-I in the process of haematopoiesis. The present investigation has been undertaken to study the in vitro effect of MCP-I on myeloid haematopoiesis using murine non adherent bone marrow cells and to characterize the molecular mechanism(s) underlying this event. In particular, the role of protein kinases, phosphatases and other signal intermediates involved in the signal transduction pathway leading to the MCP-Iinduced haematopoiesis was also investigated.
MATERIALS AND METHODS

Mice
Inbred strain of pathogen-free BALB/c mice of either sex, 8-10 weeks of age with an average body weight of 20-25g were used to obtain bone marrow cells. The animals were kept under controlled temperature, humidity and 12h of light and dark cycle with food and water ad libidum, Preparation of L929 cell conditioned medium L929 cell-conditioned medium (LCM) is used as a source of macrophage colony stimulating factor (MCSF) [16] . LCM was prepared according to the method described earlier [17] . L929 cells were incubated in RPMI-1640 supplemented with 10% FCS for 5-7 days. Cell free supernatant was then harvested from the confluent monolayers, passed through O.22f.lm membrane filter and stored at -20°C until use.
Bone marrow cell preparation
Bone-marrow cells (BMCs) were obtained from the femurs of mice following a method described earlier [17] . Briefly, the mice were killed by cervical dislocation and the BMCs flushed from the femoral shafts with serum-free medium. The BMCs were agitated gently to prepare a single cell suspension and then washed three times with serum-free medium by centrifugation at 1000rpm at 18°C for 10min each. BMCs were then incubated in plastic tissue culture flasks (A/S Nunc, Denmark) for 2h at 37°C to remove the adherent cells. Thereafter, the nonadherent BMCs (NABMCs) were collected and used for all experiments.
Bone-marrow cell proliferation assay
The proliferation ofthe non-adherent bone-marrow cells (NABMCs) was assayed by measuring tritiated thymidine CH-TdR) incorporation. Briefly, the NABMCs (I x l O'cells) were seeded in 200f.l1 of complete medium in each well of a 96-well tissue culture plate (A/S Nunc, Denmark) and incubated at 37°C in a humidified atmosphere of 5% CO 2 in a CO 2 incubator for 48h. l8h prior to the end of incubation, the cultures were pulsed with lu Ci/well of3H-TdR. On completion of the incubation period, the cells were then washed three times with PBS and lysed with 100f.l1 of 0.25% (w/v) SDS. The Iysates were counted for radioactivity in a liquid scintillation counter (LKB, Bromma, Sweden). The bone-marrow cell proliferation was expressed as counts per minute (CPM) of the 3H_TdR incorporation.
Bone-marrow colony forming assay
Bone-marrow colonies were prepared In methylcellulose culture as described previously [18] . Briefly, nonadherant bone marrow cells (I x I O'cells/ ml) were suspended in a mixture containing 0.9%(w/ v) methylcellulose in RPMI 1640 medium, 30% FCS and 25%(v/v) LCM with or without 100ng/ml MCP-I, in the presence or absence of recombinant MCSF (lOOU/ml), GMCSF (lOOU/ml), GCSF (lOOU/ml) or IL-3 (lOOU/ml) as indicated in the 'Results'. The mixture was gently vortexed and 1ml was plated in each well of a 6-well tissue culture plate (A/S Nunc, Denmark) and incubated at 37°C in a humidified atmosphere of 5% CO 2 in a CO 2 incubator. The plates were scored for myeloid colonies between 7-10 days of culture. An aggregate of more than 50 cells was counted as a single colony-forming unit (CFU) and identified morphologically by microscopy into the following colony types: macrophage-colony forming unit (CFU-M), granulocyte-macrophage colony forming unit (CFU-GM) and granulocytes-colony forming unit (CFU-G).
RNA isolation, reverse transcription and polymerase chain reaction (RT-PCR)
Total RNA was isolated from the murine nonadherent bone marrow cells by TRIzol reagent (GibcoBRL) as per supplier's instructions and the quantity/purity was determined spectrophoometrically. The RNA was reverse-transcribed using a "ThermoScript" kit (GibcoBRL) and amplified by PCR using the specific primers indicated below. The thermocycle conditions were 35 cycles of 94°C for 1min, 55°C for 1 min and noc for 2 min, after which an additional extension step at noc for 5 min was included. Electrophoresis of amplified DNAs was carried out on 1.5% agarose gel and stained with ethidium bromide. The primer sequences are as follows: mouse GM-CSF forward primer, 5'-GCCATCAAAGAAGCCCTAAA -3'; GM-CSF reverse primer, 3' -GAAAACACGGACGCATTACT-5'; mouse~-globin forward, 5' CCTGCAGTGTCTGATATTGTTG;~-globin reverse, 5' AACACACCATTGCGATGAA-3'. The possible contamination of any PCR component was excluded by performing a PCR reaction with these components in the absence of RT product in each set of experiment (negative control).
Preparation of cell lysates and immunoblotting
Murine non adherent bone marrow cells were cultured in medium alone or medium containing 100ng/ ml MCP-l for l5min. In some experimental sets, the nonadherent bone marrow cells were pretreated with PD98059 or wortmannin and then incubated in fresh medium containing 100ng/ml MCP-l for 15min as mentioned in Results. On completion of l5min, the BMCs were washed with ice cold phosphate buffered RESULTS using a wavelength of 570nm. The relative cell viability was calculated according to the formula:
Where, Absorbance Control represents NABMCs incubated in medium alone and Absorbance Experimental represents NABMCs treated with the inhibitor/activator or their vehicles.
Statistical analysis
All the experiments were done in triplicate and repeated at least three times. Results are represented as mean ± S.D. Statistical significance of differences between test groups was analyzed by students t-test (two-tailed).
x 100
Absorbance Experimental
Absorbance Control Relativecell viability = saline containing I mM Na,V0 4 , then lysed in 50f.l1 of lysis buffer [20mM Tris-HCI, pH 8, 137 mM NaCI, 10% glycerol (v/v), I % Triton X-IOO (v/v), I mM Na,V0 4 , 2 mM EDTA, ImM PMSF, 20f.lM leupeptin and 0.15 units/ml aprotonin] for 20 minutes at 4°C. The Iysates were centrifuged at 13000x g for 15min. and the supernatants (containing Triton X-IOO soluble proteins) were separated on 10% SDS-polyacrylamide gels at 20 rnA. The separated proteins were transferred to nitrocellulose (8 hr at 125 rnA) and immunoblotted using the respecti ve primary antibodies, horseradish peroxidase tagged second antibody and visualized by the Chemiluminescence Western Blotting Kit (Santa Cruz Biotechnology, California, USA).
Densitometric Analysis
Densitometric studies were carried out using the software 'Gene Tools', from SYNGENE (a division of Synoptics Ltd., UK)
Percentage Viability by MTT Assay
Percentage viability of murine non-adherent bone marrow cells were determined by MTT [3(4,5);dimethyl thiazol-2,5-diphenyl tetrazolium bromide] assay as described earlier [19] . Briefly, NABMCs (IO'cells/ well) cultured in a 96-well tissue culture plate (A/S Nunc, Denmark) were treated with the recommended doses ofthe inhibitors/activators and their corresponding vehicles for varying time periods according to the culture durations. Thereafter, 1Of.l1 of 5mg/ml MTT was added to each well and the cells were incubated for 4h. A purple formazan product formed, which was solubilized by the addition of IOOf.l1 of acidic isopropanol (0.04N HCI in isopropanol) . The absorbance of each well was measured with a microplate ELISA reader
MCP-l induces the proliferation of murine bone marrow cells in vitro :
The proliferation of quiescent HPCs is an essential step in the regulation of haematopoiesis [20] . In relation to this fact, the effect of MCP-l on the proliferation of non-adherent murine bone marrow cells was studied in vitro over a period of 48h using 3H-thymidine labeled NABMCs as indicated in 'Materials and Methods'. Figure I shows that MCP-l alone or in combination with MCSF induced significant in vitro proliferation of murine NABMCs. While MCP-l itself caused a modest increase in the proliferation ofNABMCs, combination treatment of MCP-l with MCSF dramatically enhanced the NABMC proliferation as compared to the untreated or only MCSFtreated NABMCs. This response was dose-specific and occurred maximally at a dose range of SO-100ng/ml MCP-I. The viability of the NABMC culture by MTT test revealed no significant change on MCP-I treatment (data not shown).
. Expression of(A) Lyn, (B) phospho-p42/44 MAPK and (C) phospho-STAT5 (Tyr 693) in MCP-I-treated murine bone marrow cells. Nonadherent bon e marrow cells ( Ix IO'cell/ml) were incubated in medium alone or medium conta ining 100ng/ml MCP-I or pretreated with the indicated inhibitors follow ed by activation with 100ng/ml MCP-I, for 15min. The ce ll lysates prepared thereafter were separated on a 10% 5DS-PAGE ge l, transferred to nitrocellulose and probed with the respective antibodies as described in 'Materials and Methods
MCP-I induces murine bone marrow cells for enhanced myeloid colony formation in vitro
The effect ofMCP-1 treatment on the colony forming ability of the myeloid progenitors present in the murine bone marrow was studied by culturing the NABMCs in vitro for 10days in the presence of various CSFs. As evident from Figure 2 , MCP-I (lOOng/ml) induced both quantitative and qualitative changes in the in vitro colony forming response of murine NABMCs. While the treatment of NABMCs with MCSF (200U/ml) GMCSF (200U/ml) or GCSF (200U/ml) alone resulted in their lineage-restricted differentiation predominantly into macrophage type (CFU-M), granulocyte-macrophage type (CFU-GM) or granulocyte type (CFU-G) colonies respectively, the presence ofMCP-1 (I OOng/ml) in combination with the CSFs resulted in a significant increase in the total number of myeloid colonies and the frequency of the individual colony types in comparison to the untreated NABMCs or those treated with CSFs only. In most cases, the MCP-I treatment resulted in a high proportion ofCFU-GM and CFU-G. The maximal colony forming response was observed for NABMCs treated with IL-3 (200U/ml) and MCP-I, which induced roughly equal proportions of each of the three colony types. NABMCs incubated with MCP-I in the absence of recombinant CSFs also showed enhancement in their colony forming ability. In all the above experiments, the optimal response for MCP-I was found to be at a dose range of SO-100 ng/ml MCP-I, as confirmed by our earlier experiments ( Figure I) .
The involvement of protein kinases and phosphatases in the in vitro differentiation of murine bone marrow cells in response to MCP-I
The regulatory role of protein kinases and phosphatases in the process of NABMC proliferation/differentiation in response to MCP-I was studied in vitro. For this purpose, murine NABMCs treated with specific inhibitors for various kinases and phosphatases were checked for in vitro myeloid colony formation in the presence or absence of MCP-I (I OOng/ml). The tyrosine kinase inhibitor, genistein (l Oug/rnl) and protein kinase C (PKC) inhibitor, chelenthryin chloride (I OIlM) significantly inhibited the MCP-I-induced NABMC colony formation as shown in Figure 3 . The inhibitors for phosphoinositol-3-kinase (PI3K) and MEK, i.e. wortmann in (200nM) and PD98059 (l0IlM), also exerted a significant inhibitory effect in the colony forming assay. In contrast, the presence of the serine/ threonine phosphatase inhibitor, okadaic acid (I nM) caused a significant augmentation in the total number of colonies formed by the MCP-Itreated NABMCs. Similarly, an overall increase in the number of myeloid colonies formed by the MCP-I-treated NABMCs was also detectable on incubation with the tyrosine phosphatase inhibitor, sodium orthovanadate (lOIlM). However, this effect was marginal as compared to those observed for okadaic acid. In all the above experiments, the MTT viability test confirmed that none of the doses of the inhibitors or their vehicles were cytotoxic to the NABMCs during the culture period (data not shown).
MCP-I induces the expression of GM CSF mRNA in murine bone marrow cells
Murine NABMCs were cultured in medium alone or medium containing 100ng/ml MCP-I for 12h and RT -PCR was carried out using the specific primers for murine GM CSF, following total RNA extraction, as mentioned in ' Materials and Methods'. Figure 4 shows that 100ng/ml MCP-I treatment of murine NABMCs resulted in significantly enhanced expression of GM CSF mRNA as compared to the untreated NABMCs. The usage of equal RN A template for each reaction was determined by equal expression of P-globin mRNA.
MCP-I treatment to murine bone marrow cells in vitro induces the expression ofLyn, p42/ 44 MAPK and STAT 5
To investigate the signal transduction mechanism(s) underlying the in vitro proliferation of murine NABMCs in response to MCP-I, the expression of several signal intermediates typically involved in mitogenic responses ofhaematopoetic cells was studied. These include the study of the expression of src family tyrosine kinase Lyn, phospho-p42/44 MAPK (Thr 202/Tyr 204) and phospho-STAT5 (Tyr694) in the murine NABMCs following MCP-l (1 OOng/ml) stimulation. In contrast to the untreated NABMCs, MCP-l treatment caused enhanced expression of Lyn and phosphorylated p42/44 MAPK, STAT5 in the NABMCs as evident by the immunoblots (Figure 5 ). The inhibitors for MEK and PI3K, PD98059 (I O!J.M) and wortmannin (200nM), caused a drastic inhibition in the expression of both phospho-p42/44 MAPK and phospho-STAT 5. Equal loading for the phospho-specific immunoblots was ascertained by reprobing the blots with ERK and STAT 5 antibodies (data not shown).
DISCUSSION
Recent reports have suggested the regulatory role of chemokines on the movement of haematopoietic progenitor cells in and out of the "haematopoietic niche" in the bone marrow where these cells proliferate and differentiate in response to a number of specific or non-specific growth/ survival factors [5] . We have investigated the in vitro effect of MCP-I on murine bone marrow haematopoiesis, in the presence or absence of various colony-stimulating factors (CSFs), which are crucial to the growth, survival and lineagerestricted differentiation of myeloid progenitor cells (MPCs) in the bone marrow microenvironment [21] . It is observed that MCP-1 in combination with the recombinant CSFs significantly enhanced the in vitro proliferation and the myeloid colony forming ability of the murine NABMCs, as compared to the untreated or only CSF-treated cells. The response to MCP-I treatment was concentration-dependent, maximal effect being observed within a dose range of 50-1DOng/m!. Several CC and CXC chemokines have been reported earlier to positively or negatively modulate the proliferation of myeloid progenitors that respond to stimulation by single or combination ofgrowth factors [22] . In particular, MIP-la and MIP-2 have been shown to enhance colony formation by the mature murine MPC subsets in response to murine GMCSF or MCSF [6] [7] [8] . The enhancing effect ofMCP-l on NABMC proliferation and colony formation in combination with the CSFs was also validated by similar observations in the case of MCP-I-treated NABMCs in the absence of any recombinant CSFs. Supporting the present data, MCP-2 and MCP-3 have also been reported to exert nonsuppressive effect on the differentiation of GM progenitors [23] . Haematopoietic abnormalities in the behavior of the myeloid progenitor cells in CCR2-/-mice also support the above observations [24] .
The majority of the chemokine show a suppressive effect on progenitor cell proliferation/ differentiation, with eotaxin and SDF-la being the only exception [25] [26] . However, the apparent contradiction between our observations and those of others could be explained by the fact that the proliferati ve effects of the same chemokine under different growth condi tions, could be ei ther positive or suppressive, depending on the type, maturity and cytokine responsiveness of the particular target haematopoietic progenitor cells [5, 8] . This is true for CC chemokines MIP-Ia, MIP-2 [6, 7] . Therefore, the possibility that the enhancing effect of MCP-I on bone marrow colony formation could be actually an effect on the relatively mature subtypes of myeloid progenitors present in the NABMCs, seems relevant. This is supported by the observation that the murine BMCs treated with MCP-l alone or MCP-l in combination with the recombinant CSFs, preferential1y differentiate towards the granulocytic lineage (evident from the increased proportion of G-CFU and GM-CFU) irrespective of the type of CSFs used, signifying that a large population of the BMC myeloid progenitors may have been already primed to differentiate towards the granulocytic lineage. Such a possibility is conceivable considering the well-documented role of MCP-l in inflammation/malignancies, both of which are invariably associated with expansion of granulocyte population and their increased tissue infiltration [27, 28] .
Although the present data suggests a modulatory role for MCP-l in murine bone marrow haematopoiesis, the mechanism(s) underlying this event is not evident. The effect of MCP-I could be a direct, acting on the immature progenitor cel1s themselves as noted by other reports for chemokines action on single progenitor cells [29] .
Conversely, an indirect effect mediated by the generation of a local blend of growth stimulatory cytokines, which promote the proliferation, and differentiation of the murine BMCs, could also be possible. Preliminary data on enhanced expression ofGM-CSF mRNA in murine NABMCs and the production of IL-I in blood monocytes on MCP-I treatment [12] support this idea. Both these cytokines have well-established role in haematopoiesis [21, [30] [31] [32] .
The intracellular signal transduction mechanism involved in the proliferation/ differentiation of murine NABMCs in response to MCP-I, suggested the involvement of PKC, P13K and p42/44 MAPK. This was evident from the inhibitory effect of chelenthryin chloride, wortmannin and PD98059 on the MCP-I-induced myeloid colony formation. Activation ofp42/44 MAPK was detected by phospho-p42/44 MAPK expression in MCP-I-treated NABMCs by immunoblotting. The expression ofphospho-p42/ 44MAPK was confirmed by the inhibitory effect of PD98059, while the inhibition caused by wortmannin suggested the involvement of P13K. Conforming to this observation, chemokines have been shown to elicit P13K/MAPK signaling cascade that are typical for cell acti vation and mitogenesis [33] . The invol vement of receptor-associated src family tyrosine kinase, Lyn and the activation of downstream transcription factor ST AT5 in the MCP-I-induced signal pathway in NABMCs was also implicated from the immunoblot results. The inhibition of MCP-I-induced BMC colony formation with genistein further confirms the role of tyrosine kinases in in vitro BMC differentiation. Both Lyn and STAT5 have been previously reported to be associated with signal transduction in haematopoietic cells [34] .
Recent studies with SHIP-I-and motheaten mice have indicated an essential role for the protein tyrosine phosphatases in the chemokineinduced signaling in matured haematopoiesis progenitor cells and downstream effects including in vitro colony formation [35, 36] . Although, the results of our study with okadaic acid demonstrated an augmentation in the overall myeloid colony formation by the MCP-I-treated NABMCs, indicative of the possible involvement of serine/ threonine phosphatases in this process, the contribution of tyrosine phosphatases could not be clarified due to the marginal upregulation afforded by sodium orthovanadate on the MCP-I-induced in vitro colony formation.
The current investigation presents evidences for the ability of MCP-I to stimulate the proliferation and differentiation of murine NABMCs in vitro and implicates for the first time a P13K/PKC/MAPK-mediated mitogenic signal transduction pathway for this event. These observations extend the immunomodulatory role of MCP-I to bone-marrow haematopoiesis.
